• Citius Oncology reported sustained skin-related quality-of-life improvements among patients responding to LYMPHIR in pivotal Study 302 for relapsed or refractory cutaneous T-cell lymphoma.
• Results were presented at the EORTC-CLTG annual meeting in Berlin, held Oct. 8-10, 2026.
• Responders reported better overall quality of life at treatment completion; nearly a third of heavily pretreated patients with significant itch experienced sustained relief.
• Quality-of-life findings were exploratory; the trial was not designed to evaluate these outcomes, with no formal statistical comparisons performed.
• Study 302 supported FDA approval of LYMPHIR; the quality-of-life results are not included in its prescribing information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611041345PR_NEWS_USPR_____NY89068) on November 04, 2026, and is solely responsible for the information contained therein.